Author

Shashi Adsul 1

1 Takeda,Zurich,Switzerland

LONG-TERM TREATMENT WITH SUBCUTANEOUS VEDOLIZUMAB IN CROHN’S DISEASE: INTERIM RESULTS FROM THE VISIBLE OPEN-LABEL EXTENSION STUDY

Silvio Danese, Krisztina Kisfalvi, Severine Vermeire, Wenwen Zhang, Siddharth Bhatia, William J. Sandborn, Shashi Adsul

LONG-TERM TREATMENT WITH VEDOLIZUMAB SC IN ULCERATIVE COLITIS: INTERIM RESULTS FROM VISIBLE OLE

Severine Vermeire, Silvio Danese, Krisztina Kisfalvi, Wenwen Zhang, Shashi Adsul, Siddharth Bhatia, William Sandborn

REAL-WORLD EVIDENCE OF VEDOLIZUMAB ACHIEVING MUCOSAL HEALING AND ENDOSCOPIC IMPROVEMENT IN PATIENTS WITH ULCERATIVE COLITIS

Caroline Shaw, Rebecca Brown, Song Wang, Shashi Adsul, Christian Agboton, Pravin Kamble

SIMPLIFIED RULES TO IDENTIFY BIO-NAÏVE PATIENTS WITH CROHN’S DISEASE WITH HIGHER LIKELIHOOD OF CLINICAL REMISSION WHEN INITIATING VEDOLIZUMAB VERSUS ANTI-TNF THERAPIES: ANALYSIS OF EVOLVE STUDY DATA

Gerassimos J. Mantzaris, Andres Yarur, Annie Guerin, Pravin Kamble, Michelle Luo, Song Wang, Ha Nguyen, Emma Billmyer, Brian Bressler, Shashi Adsul

VEDOLIZUMAB ACHIEVES CORTICOSTEROID-FREE CLINICAL RESPONSE AND REMISSION IN INFLAMMATORY BOWEL DISEASE: A REAL-WORLD META-ANALYSIS

Caroline Shaw, Rebecca Brown, Song Wang, Shashi Adsul, Christian Agboton, Pravin Kamble

Item 1 - 5 / 5
1